Last SFr.853.00 CHF
Change Today -11.00 / -1.27%
Volume 13.8K
GALN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
OTC US
Frankfurt
OTC US
As of 11:43 AM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

galenica ag-reg (GALN) Snapshot

Open
SFr.865.00
Previous Close
SFr.864.00
Day High
SFr.865.00
Day Low
SFr.849.00
52 Week High
03/6/14 - SFr.971.00
52 Week Low
07/12/13 - SFr.607.00
Market Cap
5.5B
Average Volume 10 Days
11.8K
EPS TTM
SFr.45.71
Shares Outstanding
6.5M
EX-Date
05/13/14
P/E TM
18.7x
Dividend
SFr.14.00
Dividend Yield
1.64%
Current Stock Chart for GALENICA AG-REG (GALN)

Related News

No related news articles were found.

galenica ag-reg (GALN) Related Businessweek News

No Related Businessweek News Found

galenica ag-reg (GALN) Details

Galenica Ltd. develops, manufactures, and markets pharmaceutical products in Switzerland and internationally. Its Pharma segment offers iron replacement products, including Ferinject/Injectafer, Venofer, and Maltofer; immuno-stimulant products, such as Broncho-Vaxom and Uro-Vaxom; infectious diseases/OTX products, over-the-counter products, and herbal remedies; and synthetic and biotech drugs for use in immunology and the treatment of infectious diseases. This segment also provides products for patients suffering from chronic kidney disease; develops and markets CellCept for various applications involving autoimmune diseases; and markets products manufactured by third parties. The company’s Logistics segment offers pre-wholesale logistics services, including storage and distribution of products, and debt collection services to pharmaceutical and healthcare companies; supplies healthcare products to pharmacies, physicians, drug stores, care homes, and hospitals; and handles and coordinates the purchase, sale, warehousing, and distribution of products for third parties. Its Retail segment operates 483 pharmacies, including 312 own pharmacies and 171 partner pharmacies under the Amavita and Sun Store brands in Switzerland. This segment also operates a chain of 55 own pharmacies in partnership under the Coop Vitality brand; MediService specialty pharmacy that offers medication for the treatment of patients in their own homes; and 160 Winconcept partner pharmacies. The company’s HealthCare Information segment provides master data systems for the healthcare market; and publishes printed and electronic technical information on pharmaceutical products. This segment also maintains databases; offers management solutions under the Triamun brand name; TriaPharm total management software solution for pharmacies; TriaMed software for physicians; and TriaOne non-sector specific ERP solution for retail. Galenica Ltd. was founded in 1927 and is headquartered in Bern, Switzerland.

5,241 Employees
Last Reported Date: 03/11/14
Founded in 1927

galenica ag-reg (GALN) Top Compensated Officers

Chief Executive Officer, Head of the Pharma D...
Total Annual Compensation: SFr.1.4M
Compensation as of Fiscal Year 2013.

galenica ag-reg (GALN) Key Developments

Galenica Ltd. Presents at Kepler Cheuvreux’s 15th Swiss Small and Mid Cap Seminar, Apr-02-2014 03:40 PM

Galenica Ltd. Presents at Kepler Cheuvreux’s 15th Swiss Small and Mid Cap Seminar, Apr-02-2014 03:40 PM. Venue: The Park Hyatt Hotel, Beethovenstrasse 21, CH8002 Zurich, Switzerland. Speakers: Jörg Kneubühler, Chief Financial Officer and Head of Human Resources, Julien Vignot, Head of CorporateTreasury & Insurance.

Galenica AG Proposes Dividend for 2013; Announces Consolidated Earnings Results for the Year 2013; Provides Earnings Guidance for the Year 2014

The board of directors of Galenica AG will propose a dividend hike to CHF 14.00 per registered share from CHF 11.00 a year earlier. The company announced consolidated earnings results for the year 2013. The company announced that its net profit jumped 21.1% to CHF 334.8 million (USD 380.4 million/EUR 274.8 million) for 2013 and the management will recommend raising the dividend. The figure was boosted by positive one-offs and the settlement of an international tax case. It grew by a double-digit percentage for the 18th consecutive year. Earnings before interest, tax, depreciation and amortisation (EBITDA) went up by 8.9% to CHF 466.2 million. Net revenue rose 2% to CHF 3.4 billion. For 2014 the company aims to achieve profit of at least the prior-year level. It will focus on the consistent execution of its key strategic projects.

Galenica Ltd. - Analyst/Investor Day

Galenica Ltd. - Analyst/Investor Day

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALN:SW SFr.853.00 CHF -11.00

GALN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AMAG Pharmaceuticals Inc $19.62 USD +0.55
Celesio AG €25.96 EUR +0.06
Fresenius Medical Care AG & Co KGaA €49.64 EUR -0.194
Rockwell Medical Inc $11.13 USD -0.27
UDG Healthcare PLC 346.00 GBp +2.50
View Industry Companies
 

Industry Analysis

GALN

Industry Average

Valuation GALN Industry Range
Price/Earnings 19.0x
Price/Sales 1.6x
Price/Book 3.7x
Price/Cash Flow 15.1x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALENICA AG-REG, please visit www.galenica.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.